Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
about
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewPostprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer50 Years of progress in the systemic therapy of non-small cell lung cancerThe Lake Wobegon effect: are all cancer patients above average?Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsProteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patientsSequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer.Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancerPhase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.[A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancerA phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyGemcitabine for the treatment of advanced nonsmall cell lung cancerAssessing non-inferiority with time-to-event data via the method of non-parametric covariance.Novel non-operative treatment and treatment strategies in pancreatic cancer.Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancerGene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Novel combination chemotherapy in the treatment of non-small cell lung cancer.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineMolecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancerTreatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.
P2860
Q24200518-52E06949-D50F-4135-9177-BECC2A87053CQ24243664-4066E78B-06DC-4681-AC62-223F1F0AB9C5Q24652337-89D30DE1-6582-4326-9AD2-9EDB5B08FD68Q24678961-9C0D44B8-BDE5-4845-AD2F-8131BDC51505Q26829939-99C299E5-44F7-4AA9-A08F-F15837DDE8A9Q27014978-95FFEA05-A7C9-4DD5-84CA-A6EA8EB39581Q28303620-E6449094-6A06-44BE-8D6D-474B6FD47466Q28364203-EF67D61C-E05C-4378-BE31-4C5D97993C9CQ28533753-86EA2793-C261-4D99-807C-A6668B3CC041Q31026775-EB884E9F-7C84-41DD-AAF5-0D6E5D57C02CQ33338040-F1C67F5D-1249-4F5D-9AC1-F84DB12AAE13Q33340278-ACDAE84E-0F13-4D42-A752-1A0EE2EBD293Q33341208-F0483A4F-8DAF-430D-87D1-2339F71B9BB0Q33341211-AC569C4A-08C3-4A38-B59E-745B545DEEC4Q33343275-DE23F994-4D06-41F0-BB6D-E58510851D4FQ33343719-6B1C1256-980D-4BDB-9B95-B12442A2A9C1Q33344553-E17AF52F-C2FC-4FFB-824A-0CFB8D12B283Q33348744-56500855-81D6-486E-9393-D89D6FE573DBQ33360013-7A9DAE54-1AFE-44D5-9800-C5E60D77468AQ33360840-27D4FA29-3DA0-4360-9550-01983A86948BQ33366782-5879C719-3C36-4A4A-88FC-80A78CBCFDD2Q33375704-FDB94619-8520-47F4-AB83-D648DAAEC0E8Q33387995-04500316-F636-47C7-B6BE-BF93FD7E02F6Q33391099-F05F45B5-EAB0-4793-B6B3-A77BA0C3A256Q33399148-2557B5A5-82E0-4485-889D-91931932EFEBQ33403798-55005349-A45B-4A2B-9817-86061D250030Q33408330-5CD6C28B-1542-43E2-BE1F-90CC37405AF7Q33427467-2E27356D-4094-4927-BD92-3364D58BE3AFQ33430874-350085F0-0B43-4E79-B714-B08013889AB5Q33885578-CDAA0D8E-EB58-43E5-9F93-4E7F3C1C04A3Q33915997-617789EC-1E1C-4866-9C4E-1B5B0FDF345EQ33943160-6D725828-9EA5-47E3-AE11-73C8DA2B7CFBQ34074879-F52C3354-99BA-4BBD-9EC2-52BA30F21AD0Q34102132-E7C99FB4-A0B2-408C-A45C-310697DDCE43Q34177223-02CF019B-7CE7-401F-9DBE-7186D48FF507Q34181910-CAD552F8-0E12-440D-9E7B-23ABE822531EQ34203414-A470E020-52E8-4006-9464-516727A212A6Q34217662-3E152A09-4A74-4236-A83D-0A4ABE8E1DCFQ34243500-9DE5EFD3-4EFB-4B37-AE63-25906C09561FQ34325219-DC18B0FA-480C-4370-B963-4E3272BBAEC5
P2860
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@ast
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@en
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@nl
type
label
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@ast
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@en
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@nl
prefLabel
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@ast
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@en
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@nl
P2093
P1476
Phase III trial of gemcitabine ...... ic non-small-cell lung cancer.
@en
P2093
A B Sandler
C Manegold
C Niyikiza
J Nemunaitis
J von Pawel
L H Einhorn
P304
P356
10.1200/JCO.2000.18.1.122
P407
P577
2000-01-01T00:00:00Z